Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
XOM Exxon Mobil Corp
EPD Enterprise Products Partners LP
STLB Sterling Business Solutions Inc
CITY Avalon Correctional Services Inc
TEVJF Teva Pharmaceutical Industries Ltd
UMBF UMB Financial Corp
OXM Oxford Industries Inc
ICON Iconix Brand Group Inc
BAC Bank of America Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Price
Delayed
$14.68
Day's Change
0.6036 (4.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.77
Day's Low
14.15
Volume
(Average)

Today's volume of 3,887,446 shares is on pace to be in-line with INO's 10-day average volume of 37,817,366 shares.

3,887,446

Company Profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
853.10x
Price/Book (MRQ)
11.15x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2020
Current Month
22.1M
Previous Month
20.7M
Percent of Float
15.55%
Days to Cover
0.3839 Days

Share Information

INO is in a share class of common stock
Float
154.1M
Shares Outstanding
158.1M
Institutions Holding Shares
177
26.03%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Simon X. BenitoChmn.
  • Jong Joseph KimCEO
  • Peter D. KiesCFO
  • Jacqueline Elizabeth Elizabeth SheaCOO
  • Laurent M HumeauCSO

Address

Insider Trading

During the most recent quarter, 23K shares were bought, and 22K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.